Hormone Therapy, Estrogen Metabolism, and Risk of Breast Cancer in the Women’s Health Initiative Hormone Therapy Trial

BACKGROUND: In the Women’s Health Initiative Hormone Trials (WHI-HT), breast cancer risk was increased with estrogen plus progestin (E+P) but not with unopposed estrogen (E-alone). We hypothesized that E+P would preferentially metabolize to 16α-hydroxyestrone (16α-OHE1) rather than 2-hydroxyestrone...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Mackey, Rachel H., Fanelli, Theresa J., Modugno, Francesmary, Cauley, Jane A., McTigue, Kathleen M., Brooks, Maria Mori, Chlebowski, Rowan T., Manson, JoAnn E., Klug, Thomas, Kip, Kevin E., Curb, J. David, Kuller, Lewis H.
Formato: Artigo
Idioma:Inglês
Publicado em: 2012
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3493689/
https://ncbi.nlm.nih.gov/pubmed/22933427
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1055-9965.EPI-12-0759
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados